Unveiling Potential of DNA Polymerase III Inhibitors to Limit Helicobacter pylori

webinar

Thu, 28 Jul 2022, 16:00 CEST (Berlin)

Dr. Sumera Zaib, University of Central Punjab (UCP), Pakistan

Unveiling Potential of DNA Polymerase III Inhibitors to Limit Helicobacter pylori

Helicobacter pylori is the most common gram-negative pathogen that causes chronic gastric inflammation and may lead to gastric cancer. To date, it is hard to eradicate and manage H. pylori infections but with limited combination therapies consistent efforts are in process. However, the immense and repetitive use of the same combination therapies over time made the bacterium resistant to several drugs. Consequently, H. pylori has been considered as a serious threat to human health and require novel antimicrobial drug candidates.

Considering the resistance mechanisms of H. pylori, the DNA polymerase III subunit β (DnaN) was selected as the drug target against which several inhibitors were optimized. Some of the inhibitors were found to be highly potent inhibitors of DnaN as evaluated by utilizing built-in libraries of BioSolveIT, infiniSee, CoLibri, FTrees, SeeSAR’s Inspirator and Molecule Editor Mode, and ReCore. We have discovered a benzamide derivatives as lead class of inhibitor for DnaN via AI- based docking, virtual screening, molecular editing, and toxicological investigation.

Looking forward to your active participation.

Current news

CHEMriya Update November
November 11, 2026 11:19 CET
More Chemistry. More Possibilities. The latest update of CHEMriya brings over 794 billion virtual product molecules to your compound exploration. Developed by OTAVA in collaboration with BioSolveIT, this on-demand Chemical Space opens up new opportunities for hit expansion, hit-to-lead optimization, and compound evolution. The November 2026 release combines OTAVA’s chemistry...
Read on
category
Challenge
Winter 2026 Scientific Challenge Deadline Approaching
November 3, 2026 13:18 CET
The Winter 2026 Scientific Challenge is here! We invite researchers from academia (students, postdocs, and professors), non-profit organizations, and independent researchers to take part. Whether you are exploring a new drug discovery idea or looking to advance an existing project, our software can help you take your research further. How...
Read on
CORE by Onepot.AI – Access now with our tools
October 27, 2026 14:38 CET
Bringing Robotic Synthesis to Chemical Space Exploration A new Chemical Space is now available for your compound exploration: onepot’s CORE Space brings over 10 billion virtual product molecules to your drug discovery projects. CORE (Compounds On-demand via Robotic Execution) combines reactions widely used in medicinal chemistry with building blocks that...
Read on